WOBURN, Mass., Jan. 2 BioVex Inc today announced that itwill present at the JPMorgan 26th Annual Healthcare Conference at 2:30 p.m. PTon Wednesday, January 9, 2008. The conference is being held at Westin St.Francis in San Francisco, California.
BioVex is an end-of-Phase II clinical-stage biotechnology company based inWoburn, MA, focused on the development and commercialization of biologicaltreatments for cancer and the prevention of infectious disease. The companyhas two proprietary technology platforms: OncoVEX and ImmunoVEX.
BioVex's lead cancer program, OncoVEX GM-CSF, is an oncolytic vaccine thatselectively destroys tumor cells accompanied by the induction of a systemicimmune response. OncoVEX GM-CSF is currently completing a Phase II clinicaltrial for melanoma and Phase I/II clinical trials for head & neck cancer andpancreatic cancer. Data from these studies has been very encouragingdemonstrating OncoVEX GM-CSF has the potential to treat both local andmetastatic disease. The Company is currently preparing for an initialregistration study in melanoma where multiple overall durable complete andpartial responses have been demonstrated in an ongoing Phase II trial testingOncoVEX GM-CSF as stand alone therapy in patients with un-resectable stageIIIc and stage IV metastatic disease. The Company plans to make an SPAsubmission to the FDA early in the first quarter of 2008.
The Company's second program is a rationally designed live attenuatedvaccine for genital herpes, ImmunoVEX HSV2, based on the novel concept ofremoving key genes responsible for immune evasion. The vaccine providescomplete protection in animal models of the disease. A Phase I study withImmunoVEX HSV2 is scheduled to commence in the first quarter of 2008.
SOURCE BioVex Inc